Eli Lilly's stock has shown a low correlation of 0.31 to the S&P 500 over the past five years, meaning most of its returns have been driven by its own business rather than broad market swings. Over the past year, the stock captured about 81% of the market's gains on up days but only 34% of the losses on down days, demonstrating favorable asymmetry. This has contributed to a risk-adjusted return of 1.13 over five years, compared to 0.61 for the S&P 500. The company's revenue grew 56% year-over-year in the latest quarter, driven by Mounjaro and Zepbound, which together brought in $12.8 billion, and it raised full-year revenue guidance by $2 billion. However, the stock trades at a price-to-earnings ratio of 42.8, and management expects pricing headwinds in the low to mid-teens for the full year as it works to secure broader insurance coverage for its obesity treatments.
Eli Lilly and CompanyRevenue grew 56% YoY driven by Mounjaro and Zepbound, and full-year guidance raised by $2 billion
AbbVie Inc
Amgen Inc
Merck & Company Inc
Pfizer Inc